Investment Thesis
BeyondSpring is a pre-revenue pharmaceutical company with negative stockholders equity of -$34.5M, indicating technical insolvency on a book value basis. With only $4.0M cash against annual operating burn of -$3.3M, the company faces critical liquidity constraints and approximately 12-16 months of runway absent capital infusion or commercialization breakthrough.
Strengths
- Modest cash position of $4.0M provides near-term operational buffer
- Pharmaceutical sector with implied clinical pipeline in development
- Recent insider activity (7 Form 4 filings) suggests management engagement
Risks
- Negative stockholders equity of -$34.5M indicates balance sheet insolvency and structural financial distress
- Zero revenue generation with no FDA-approved products; entirely pre-commercial stage with execution risk
- Operating cash burn of -$3.3M annually against limited cash creates severe funding urgency within 12-16 months
- Liabilities of $48.8M exceed assets by $30.4M; limited debt servicing capacity without dilutive capital raises
- Current ratio of 1.09x indicates tight liquidity with minimal margin for adverse developments
Key Metrics to Watch
- Cash balance depletion rate and remaining runway to next funding event
- Clinical trial progression and FDA regulatory milestones toward revenue-generating approvals
- Quarterly operating cash burn trends and burn rate acceleration indicators
- Capital raise activity and dilution impact on existing shareholders
Financial Metrics
Revenue
0.0
Net Income
-2.2M
EPS (Diluted)
$-0.03
Free Cash Flow
-3.3M
Total Assets
18.4M
Cash
4.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-11.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.09x
Quick Ratio
1.09x
Debt/Equity
N/A
Debt/Assets
264.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:30:07.892847 |
Data as of: 2026-03-31 |
Powered by Claude AI